Modality
Peptide
MOA
STINGag
Target
PCSK9
Pathway
Notch
Gastric CaHNSCCCML
Development Pipeline
Preclinical
May 2024
→ Nov 2026
PreclinicalCurrent
NCT05878698
1,342 pts·CML
2024-05→2026-11·Recruiting
1,342 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-158mo awayInterim· CML
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2026-11-15 · 8mo away
CML
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05878698 | Preclinical | CML | Recruiting | 1342 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |